It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The formation of new ribosomes is tightly coordinated with cell growth and proliferation. In eukaryotes, the correct assembly of all ribosomal proteins and RNAs follows an intricate scheme of maturation and rearrangement steps across three cellular compartments: the nucleolus, nucleoplasm, and cytoplasm. We demonstrate that usnic acid, a lichen secondary metabolite, inhibits the maturation of the large ribosomal subunit in yeast. We combine biochemical characterization of pre-ribosomal particles with a quantitative single-particle cryo-EM approach to monitor changes in nucleolar particle populations upon drug treatment. Usnic acid rapidly blocks the transition from nucleolar state B to C of Nsa1-associated pre-ribosomes, depleting key maturation factors such as Dbp10 and hindering pre-rRNA processing. This primary nucleolar block rapidly rebounds on earlier stages of the pathway which highlights the regulatory linkages between different steps. In summary, we provide an in-depth characterization of the effect of usnic acid on ribosome biogenesis, which may have implications for its reported anti-cancer activities.
Usnic acid is a lichen secondary metabolite and has a antitumor activity. Here the authors show that usnic acid rapidly blocks large ribosomal subunit formation. This hinders pre-rRNA processing and leads to depletion of key maturation factors such as Dbp10.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 University of Graz, Institute of Molecular Biosciences, Graz, Austria (GRID:grid.5110.5) (ISNI:0000 0001 2153 9003)
2 Vienna BioCenter, Research Institute of Molecular Pathology (IMP), Vienna, Austria (GRID:grid.473822.8) (ISNI:0000 0005 0375 3232); Doctoral School of the University of Vienna and Medical University of Vienna, Vienna BioCenter PhD Program, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
3 German Center for Environmental Health GmbH, Core Facility Metabolomics and Proteomics (CF-MPC), Helmholtz Center Munich, Munich, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525)
4 Vienna BioCenter, Research Institute of Molecular Pathology (IMP), Vienna, Austria (GRID:grid.473822.8) (ISNI:0000 0005 0375 3232)
5 Institute of Science and Technology Austria, Klosterneuburg, Austria (GRID:grid.33565.36) (ISNI:0000 0004 0431 2247)
6 Graz University of Technology, Institute of Organic Chemistry, Graz, Austria (GRID:grid.410413.3) (ISNI:0000 0001 2294 748X)